NCT03464201 - Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 13, 2018

Primary Completion Date

November 11, 2020

Study Completion Date

November 11, 2020

Conditions

Ovarian Cancer

Interventions

DRUG

Enzalutamide 40 MG

Enzalutamide 160 mg p.o. every day

Trial Locations (8)

Hospital de Mar, Barcelona

Hospital Reina Sofia, Córdoba

Hospital Madrid Sanchinarro (CIOCC), Madrid

Hospital Universitario La Paz, Madrid

Hospital Son Llatzer, Palma de Mallorca

Hospital de Navarra, Pamplona

Complejo Hospitalario Universitario de Santiago, Santiago de Compostela

Hospital La Fe, Valencia